PRIALT® Assurance

ESTEVE | PRIALT® (ZICONOTIDE) INTRATHECAL INFUSION

Practice Enrollment Form

Please complete and submit by emailing to reimbursement@esteve.com.
UNREDACTED PATIENT INFORMATION WILL NOT BE ACCEPTED.

1 PRACTICE INFORMATION

Practice Name: _____

Site Name (if applicable): _____

Site Address: _____

City: _____ State: _____ ZIP: _____

Office Contact: _____ Office Email: _____

2 PROGRAM GUIDELINES

This agreement confirms that the purchasing physician and provider site understands and agrees to the following terms of the ESTEVE PRIALT Assurance Program:

1. The practice is only required to submit this enrollment form once to enroll in the ESTEVE PRIALT Assurance Program. This can be completed after the patient receives treatment.
2. The ESTEVE PRIALT Assurance Program is for patients who have insurance with confirmed coverage for PRIALT.
3. ESTEVE Together must conduct and document a benefit verification for PRIALT before a patient receives treatment.
4. If ESTEVE Together confirmed that the patient has coverage for PRIALT, that is prescribed by the patient's physician, the claim may be eligible for replacement product under the Program. The provider must then follow all payer guidelines (prior authorizations, pre-determinations, etc) and timely file all claims and appeals in accordance with payer policy.
5. If the appropriately billed claim(s) is (are) denied, the provider will send a redacted copy of the claim(s) submitted, all explanation of benefits (EOB) to the program, and documents related to the benefit verification by ESTEVE Together. Partial payment is not considered a denial.
6. The provider must submit at least one level of appeal following all payer guidelines. If the claim is denied again (not partially paid), the provider will be eligible to receive replacement product upon receipt of all required documentation. Requested documentation includes redacted claim submission, patient EOB, and first-level appeal denial by the patient's insurance provider (only required for initial denied date of service).
7. To be eligible for a replacement, PRIALT must be purchased through McKesson Specialty and used as monotherapy.
8. The ESTEVE PRIALT Assurance Program is not payer specific. Both physician offices and hospitals are eligible if PRIALT is given to an insured patient on an outpatient basis.
9. Request for replacement product must occur within six months of the patient's treatment date.
10. The ESTEVE PRIALT Assurance Program is limited to two replacement products per calendar year, per physician, so long as the payers are different for each claim.
11. If the claim does not meet the above guidelines, then PRIALT is not eligible for replacement product by the ESTEVE PRIALT Assurance Program and will not be subject to the benefits of the program.
12. Agree to return any copayment, co-insurance, or any other payments made by patient or the payer, or any other party specific to the ESTEVE PRIALT Assurance Program and the replacement product being issued.
13. The ESTEVE PRIALT Assurance Program reserves the right to make eligibility guidelines, terminate, or modify this Program at any time for any reason.
14. Understand that the ESTEVE PRIALT Assurance Program and the other product support programs offered by Esteve Pharmaceuticals LLC do not impose any purchase obligation at any time or in any manner. Use of PRIALT may be discontinued at any time, without penalty.
15. **IF UNREDACTED PATIENT INFORMATION IS SUBMITTED, IT WILL BE DELETED AND YOUR CLAIM WILL NOT BE PROCESSED.**

The individual signing below represents that he or she has the appropriate authority on behalf of the purchaser to enter into this agreement and the authority to enter into this agreement on behalf of the practice listed on this form.

Physician or Provider Contact Signature: _____ Date: _____

Name (printed): _____ Title: _____

I attest that the information supplied is complete and accurate. I understand this information is for the sole use of the program, its representatives, and/or agents selected in order to assess eligibility for participation in the PRIALT Assurance Program. I understand eligibility under the program is subject to approval under the guidelines, and that the manufacturer reserves the right to change or terminate the program without prior notice. I agree to abide by this certification throughout the practice's participation in the program and to notify the program if aspects of this certification are no longer applicable.

Please complete and submit by emailing to reimbursement@esteve.com.
UNREDACTED PATIENT INFORMATION WILL NOT BE ACCEPTED.

PRIALT, ESTEVE, and the ESTEVE logo are registered trademarks of ESTEVE Pharmaceuticals, S.A.
©2026 ESTEVE Pharmaceuticals, S.A. All rights reserved. PRIA-P-0025 (08-2026)